Carnyx Therapeutics

Carnyx Therapeutics is a preclinical-stage biopharmaceutical company focused on developing first-in-class peptide-based therapeutics to improve sleep, treat vision disorders, and extend healthspan. The company is leveraging decades of research on Epitalon, a synthetic peptide known for its potential to enhance sleep and longevity, to engineer proprietary, orally bioavailable and eye-drop analogs. Its lead programs include CNYX-005, an oral candidate designed to selectively induce restorative non-rapid eye movement (NREM) sleep, and CNYX-001, an eye-drop formulation targeting retinitis pigmentosa independent of genetic cause. Led by experienced biotech entrepreneur Dr. Patrick Gunning, Carnyx aims to overcome the delivery and stability limitations of traditional peptides to address significant unmet medical needs.